We started with the idea of establishing an innovation driven drug discovery organization in India. We are passionate about contributing towards addressing global unmet need.  We received BIRAC Ignition Grant (BIG) in support of rationally designing novel insulin analogues conducive for oral delivery. The program enabled development of in-silico platform, Sq-PROT, our proprietary peptide & protein design tool that allows multi-parametric ligand design. We have shortlisted three novel insulin lead candidates that are tolerant to gut enzyme degradation and found to be activite in mice and rats. A successful oral basal insulin will improve patient convenience and help early initiation of Insulin therapy, thus changing the treatment paradigm. 

It will be an important option for treatment of hypergycemia in Patients with Type 1 diabetes, Type 2 diabetes and cystic fibrosis.

To address the current ongoing epidemic related to opioid analgesics, and find effective therapy  for diabetic neuropathy, we have designed a peptide non-opiate analgesic that targets multiple receptors. We have selected lead candidates active against all three targets with >1000-fold selectivity to the off-targets with considerable analgesic effects in animals. Use of Sq-PROT enables design of multi-targeted ligands and reduces cost & time of discovery.

Today, we have extended our research interests beyond small molecule and biologics to RNA therapeutics. We are building a circular mRNA platform as circular mRNA represents the most promising route to building next generation, cost-effective vaccines and drugs.